Clozapine + aripiprazole: is this the new duo? - a review and analysis

Introduction

Clozapine remains the cornerstone treatment for treatment‑resistant psychotic disorders, yet its clinical utility is frequently constrained by clinically relevant cardiometabolic adverse effects, including weight gain, dyslipidemia and glucose metabolism disturbances. Aripiprazole has attracted interest as an adjunctive strategy due to its distinct action mechanism and comparatively favorable metabolic burden. In this context, the clozapine–aripiprazole duo has been repeatedly explored over the last two decades as a potentially rational approach to improve tolerability while preserving or enhancing clinical efficacy. Nevertheless, the evidence remains heterogeneous and the overall clinical relevance of this strategy is still under discussion.

Aims

This review summarizes the current literature on adjunctive aripiprazole with clozapine, focusing primarily on metabolic outcomes and tolerability, and secondly on psychopathological changes.

Methods

A literature search was conducted using PubMed, Scopus and Web of Science with the terms “aripiprazole AND clozapine AND (long acting OR injectable OR LAI OR combination)”, and studies from the last 20 years were selected. Priority was given to randomized, double‑blind, placebo‑controlled trials and systematic reviews evaluating adjunctive aripiprazole in clozapine‑treated patients.

Results

Shortly after the global introduction of aripiprazole in the 2000s, early studies suggested potential benefit of clozapine plus aripiprazole from a cardiometabolic perspective, based on modest early data. In the 2010 trial by Henderson et al., adjunctive aripiprazole did not improve the primary psychotic outcome but was associated with greater improvement in negative symptoms, lower prolactin and triglyceride levels than placebo. In the 2010 study by Chang et al., aripiprazole augmentation produced significant reductions in body weight, body mass index (BMI), waist circumference and low‑density lipoprotein cholesterol (LDL). Later, systematic reviews began to emerge. Notably, those published between 2015 and 2026 concluded that the combination may improve metabolic outcomes, while emphasizing the limited number of trials, small samples and short follow‑up periods. In particular, a 2025 systematic review and meta‑analysis of combined aripiprazole on glycolipid metabolism in schizophrenia confirmed that adjunctive therapy reduces glucose, triglycerides, total cholesterol and LDL, particularly in short‑term treatment (≤8 weeks) and with doses superior to 15 mg/day. Earlier case series and open‑label studies also reported reductions in weight, cholesterol and triglyceride levels, as well as improvements in negative symptomsand clozapine dose reductions. Across studies, the combination was generally well toleratedwithout consistent signal of clinically relevant pharmacokinetic interaction. Effects on total symptom severity and functional outcomes were not uniform, and themost consistent findings were observed in metabolic measures.

Conclusions

Current evidence suggests that adjunctive aripiprazole in clozapine‑treated patients may provide clinically meaningful metabolic benefits, including reductions in body weight, BMI, triglycerides, total cholesterol, LDL and improvements in glucose‑related parameters. However, effects on overall psychopathology are modest and/or heterogeneous, and the evidence remains limited by small samples and short‑term studies. Therefore, although the clozapine–aripiprazole duo appears promising, it should be regarded as a potentially beneficial, but still investigational, strategy pending confirmation from larger, long‑term randomized controlled trials before being considered established in routine clinical practice.

References

No references